Research programme: protein kinase inhibitors - PIQUR Therapeutics
Alternative Names: PQR-311; PQR-316; PQR-3xx; PQR-401; PQR-514; PQR-530; PQR-620Latest Information Update: 28 Mar 2021
Price :
$50 *
At a glance
- Originator PIQUR Therapeutics
- Class Antineoplastics; Eye disorder therapies; Skin disorder therapies
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Janus kinase inhibitors; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Brain disorders; Cancer; Eye disorders; Lymphoma; Skin disorders; Solid tumours
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for preclinical development in Solid-tumours in Switzerland (PO)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Lymphoma in Switzerland
- 28 May 2020 No recent reports of development identified for preclinical development in Brain-disorders in Switzerland